Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DREAMM-8: belantamab mafodotin + pomalidomide + dexamethasone versus pomalidomide + bortezomib + dexamethasone in relapsed/refractory multiple myeloma
2023-506877-37-00Phase 3Authorised
- Sponsor
- GSK
- Start
- Sep 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
- Countries
- 18
01
Overview
Phase 3, randomised, open-label trial of belantamab mafodotin, pomalidomide, bortezomib and dexamethasone in multiple myeloma (MM) (2 arms), sponsored by GSK. Primary endpoint: Progression-free survival. Planned start Sep 2020; status: authorised.
02
Drugs
belantamab mafodotinpomalidomidebortezomibdexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2023-506877-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506877-37-00.